Search Results | Cancer Research | American Association for Cancer Research

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Abstract LB061: Evaluation of the in vivo efficacy of the B7-H3 targeting antibody-drug conjugate (ADC) DS7300a: A report fro the Pediatric Preclinical In Vivo Resting (PIVOT) program

Cancer Res (2022) 82 (12_Supplement): LB061.

DOI: https://doi.org/10.1158/1538-7445.AM2022-LB061

Published: 15 June 2022

View article

Journal Articles

Abstract 203: SCLC-CellMiner: An extensive cell line genomic and pharmacology resource identifies a subgroup of small cell lung cancers sensitive to targeted therapies and immunotherapies

Cancer Res (2021) 81 (13_Supplement): 203.

DOI: https://doi.org/10.1158/1538-7445.AM2021-203

Published: 01 July 2021

View article

Journal Articles

Abstract 212: Sarcoma-CellMiner: An extensive resource for patient-derived sarcoma cell line epigenetics, genomics and pharmacology

Camille Tlemsani, Lorinc Pongor, Javed Khan, Fathi Elloumi, Sudhir Varma, Augustin Luna, Vinodh Rajapakse, Kurt Kohn, Julia Krushkal, Mirit Aladjem, Beverly Teicher, Paul Meltzer, William Reinhold, Christine Heske, Yves Pommier

Cancer Res (2021) 81 (13_Supplement): 212.

DOI: https://doi.org/10.1158/1538-7445.AM2021-212

Published: 01 July 2021

View article

Journal Articles

Abstract LB252: Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models

Douglas Harrison, Jonathan Gill, Pooja Hingorani, Michael Roth, Wendong Zhang, Beverly Teicher, Eric J. Earley, Stephen W. Erickson, Gregory Gatto, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Edward A. Kolb, Richard Gorlick

Cancer Res (2021) 81 (13_Supplement): LB252.

DOI: https://doi.org/10.1158/1538-7445.AM2021-LB252

Published: 01 July 2021

View article

Journal Articles

Abstract 3835: In vivo evaluation of the Menin inhibitor VTP-50469 against Ewing sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Peter J. Houghton, Raushan Kurmasheva, Gerard M. McGeehan, Steve W. Erickson, Beverly Teicher, Malcolm Smith

Cancer Res (2019) 79 (13_Supplement): 3835.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3835

Published: 01 July 2019

View article

Journal Articles

Abstract 3848: In vivo evaluation of the LSD1 inhibitor SP-2577 against Ewing sarcoma and rhabdomyosarcoma preclinincal models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Peter J. Houghton, Steve W. Erickson, Beverly Teicher, Malcolm A. Smith, Ruolan Han, Raushan Kurmasheva

Cancer Res (2019) 79 (13_Supplement): 3848.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3848

Published: 01 July 2019

View article

Journal Articles

Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM

Holly Lindsay, Yuchen Du, Lin Qi, Huiyuan Zhang, Sibo Zhao, Frank Braun, Mari Kogiso, Sarah Injac, Mary Sobieski, Clifford Stephan, Gordon Alton, Gregory Stein, Graham Beaton, Stephen Erickson, Beverly Teicher, Malcolm A. Smith, Xiao-Nan Li

Cancer Res (2019) 79 (13_Supplement): LB-320.

DOI: https://doi.org/10.1158/1538-7445.AM2019-LB-320

Published: 01 July 2019

View article

Journal Articles

Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts

Eric Earley, Richard Gorlick, Peter J. Houghton, John M. Maris, Xiao-Nan Li, Richard B. Lock, Beverly Teicher, Malcolm A. Smith, Stephen W. Erickson

Cancer Res (2019) 79 (13_Supplement): LB-321.

DOI: https://doi.org/10.1158/1538-7445.AM2019-LB-321

Published: 01 July 2019

View article

Journal Articles

Abstract 5872: Pediatric Preclinical Testing Consortium (PPTC) of eribulin in osteosarcoma (OS) patient-derived xenograft (PDX) models

Wendong Zhang, E. Anders Kolb, Richard Gorlick, Michael Roth, Jonathan Gill, Sudie Rowshan, Stephen Erickson, Raushan Kurmasheva, Peter Houghton, Beverly Teicher, Malcolm A. Smith

Cancer Res (2018) 78 (13_Supplement): 5872.

DOI: https://doi.org/10.1158/1538-7445.AM2018-5872

Published: 01 July 2018

View article

Journal Articles

Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint

Cancer Res (2018) 78 (9): 2166–2170.

DOI: https://doi.org/10.1158/0008-5472.CAN-17-3760

Published: 30 April 2018

View article

Journal Articles

Abstract 605: Building better cell models for screening oncology compounds

David M. Evans, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Thomas Silvers, Ralph E. Parchment, Beverly Teicher

Cancer Res (2016) 76 (14_Supplement): 605.

DOI: https://doi.org/10.1158/1538-7445.AM2016-605

Published: 15 July 2016

View article

Journal Articles

Abstract 606: Similar 3D pharmacodynamic (3D-PD) responses of human tumor spheroids and xenografts to topoisomerase 1 inhibitor-induced DNA damage

David M. Evans, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Silvers Thomas, Robert Kinders, Tony Navas, Scott Lawrence, Anne Monks, Annamaria Rapisarda, Ralph E. Parchment, James H. Doroshow, Beverly Teicher

Cancer Res (2016) 76 (14_Supplement): 606.

DOI: https://doi.org/10.1158/1538-7445.AM2016-606

Published: 15 July 2016

View article

Journal Articles

Abstract 5178: Determinants of response to temozolomide in an exceptionally sensitive patient derived model

Cancer Res (2016) 76 (14_Supplement): 5178.

DOI: https://doi.org/10.1158/1538-7445.AM2016-5178

Published: 15 July 2016

View article

Journal Articles

Abstract 3741: Development and characterization of a cell based assay for the validation of mutant IDH1 inhibitors

Nicole D. Fer, Erik Harris, Stephen Fox, Ming Zhou, Catherine Simpson, Jing Liu, Ilia Korboukh, Emily A. Hull-Ryde, William P. Janzen, Stephen V. Frye, Anne Monks, Beverly Teicher, Annamaria Rapisarda

Cancer Res (2014) 74 (19_Supplement): 3741.

DOI: https://doi.org/10.1158/1538-7445.AM2014-3741

Published: 01 October 2014

View article

Journal Articles

Abstract 5475: Interrogation of NCI-60 patterns of growth inhibition in conjunction with investigational oncology agents kinase profiling for the elucidation of mechanistic targets

Joel Morris, Mark Kunkel, Eric Polley, Susan Holbeck, Anne Monks, David Evans, Annamaria Rapisarda, Jerry Collins, Beverly Teicher

Cancer Res (2014) 74 (19_Supplement): 5475.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5475

Published: 01 October 2014

View article

Journal Articles

Abstract 5450: Screening more than 60 human SCLC lines with approved and investigational agents indicates complex patterns of response: Identification of HSP90 and HDACs as potential targets

David M. Evans, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Thomas Silvers, John Connelly, Anne Monks, Eric Polley, Gurmeet Kaur, Joel Morris, Beverly Teicher

Cancer Res (2014) 74 (19_Supplement): 5450.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5450

Published: 01 October 2014

View article

Journal Articles

Abstract 890: Interleukin 11: A novel therapeutic target in IL-11Rα expressing sarcomas

Monica Mancini, Nicole Fer, Victor Perez, Beverly Teicher, Annamaria Rapisarda

Cancer Res (2012) 72 (8_Supplement): 890.

DOI: https://doi.org/10.1158/1538-7445.AM2012-890

Published: 15 April 2012

View article

Journal Articles

Abstract #4090: In vitro and in vivo evaluation of novel VEGF-binding proteins, sFLT01 and sFLT02

Rebecca Bagley, Min Yao, Leslie Kurtzberg, William Weber, Hillard Rubin, Kerry Culm-Merdek, Christine Burnett, Lucy Yen, Elizabeth Isenberger, Cindy Rogers, Cecile Rouleau, Peter Pechan, William Brondyk, Abraham Scaria, Johanne Kaplan, Beverly Teicher

Cancer Res (2009) 69 (9_Supplement): 4090.

Published: 01 May 2009

View article

Journal Articles

Evaluation of erufosine, an alkylphosphocholine, on malignant cells and bone marrow CFU-GM

Rebecca Bagley, Cecile Rouleau, Leslie Kurtzberg, Min Yao, Beverly Teicher

Cancer Res (2008) 68 (9_Supplement): 5703.

Published: 01 May 2008

View article

Journal Articles

Bone marrow and tumor line cytotoxicity and human tumor xenograft efficacy of non-camptothecin and camptothecin Topoisomerase-I inhibitors

Leslie Kurtzberg, Traci Battle, Cecile Rouleau, Rebecca Bagley, Naoki Agata, Min Yao, Steven Schmid, Stephanie Roth, Jennifer Crawford, Roy Krumbholtz, Xian-Jie Yu, Fei Wang, Edmond LaVoie, Beverly Teicher

Cancer Res (2007) 67 (9_Supplement): 771.

Published: 01 May 2007

View article

NARROW

Abstract LB061: Evaluation of the in vivo efficacy of the B7-H3 targeting antibody-drug conjugate (ADC) DS7300a: A report fro the Pediatric Preclinical In Vivo Resting (PIVOT) program

Abstract 203: SCLC-CellMiner: An extensive cell line genomic and pharmacology resource identifies a subgroup of small cell lung cancers sensitive to targeted therapies and immunotherapies

Abstract 212: Sarcoma-CellMiner: An extensive resource for patient-derived sarcoma cell line epigenetics, genomics and pharmacology

Abstract LB252: Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models

Abstract 3835: In vivo evaluation of the Menin inhibitor VTP-50469 against Ewing sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Abstract 3848: In vivo evaluation of the LSD1 inhibitor SP-2577 against Ewing sarcoma and rhabdomyosarcoma preclinincal models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM

Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts

Abstract 5872: Pediatric Preclinical Testing Consortium (PPTC) of eribulin in osteosarcoma (OS) patient-derived xenograft (PDX) models

Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint

Abstract 605: Building better cell models for screening oncology compounds

Abstract 606: Similar 3D pharmacodynamic (3D-PD) responses of human tumor spheroids and xenografts to topoisomerase 1 inhibitor-induced DNA damage

Abstract 5178: Determinants of response to temozolomide in an exceptionally sensitive patient derived model

Abstract 3741: Development and characterization of a cell based assay for the validation of mutant IDH1 inhibitors

Abstract 5475: Interrogation of NCI-60 patterns of growth inhibition in conjunction with investigational oncology agents kinase profiling for the elucidation of mechanistic targets

Abstract 5450: Screening more than 60 human SCLC lines with approved and investigational agents indicates complex patterns of response: Identification of HSP90 and HDACs as potential targets

Abstract 890: Interleukin 11: A novel therapeutic target in IL-11Rα expressing sarcomas

Abstract #4090: In vitro and in vivo evaluation of novel VEGF-binding proteins, sFLT01 and sFLT02

Evaluation of erufosine, an alkylphosphocholine, on malignant cells and bone marrow CFU-GM

Bone marrow and tumor line cytotoxicity and human tumor xenograft efficacy of non-camptothecin and camptothecin Topoisomerase-I inhibitors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only